N/A N=20

Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF

Bacterial Infections

Bottom Line

View on ClinicalTrials.gov: NCT04358991 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2020

Primary outcome: Primary: Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients — 80.6; 15.9 mcg/mL

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Ceftazidime-avibactam (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Pittsburgh
Primary completion: Dec 2019

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Levels of Ceftazidime and Avibactam Among Critically-ill Patients	80.6; 15.9	—

Summary

Ceftazidime-avibactam is used for treatment of invasive Gram-negative bacterial infections among critically ill patients, including those on continuous venovenous hemodiafiltration . However, dosing of ceftazidime-avibactam for these patients remains undefined. The purpose of this study was to evaluate the pharmacokinetics of ceftazidime and avibactam among critically-ill patients, including those receiving CVVHD. This is a registration of Dr. Shields' exempt project under IRB approved research study STUDY19040363

Eligibility Criteria

Inclusion Criteria

Adult patients receiving ceftazidime-avibactam as standard care

Exclusion Criteria

Less than 18 years-old

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04358991). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.